Assessment of the Glycemic Responses to Nutritional Products

NCT05179031 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2022-03-15

No results posted yet for this study

Summary

This study assesses the glycemic responses to nutritional products. During a study visit fasted subjects will consume one serving of the reference product or the test product. Capillary blood samples will be taken at baseline and at several time-points over a 2-hr period. Several nutritional products will be tested over time.

Conditions

  • Glycemic Response

Interventions

DIETARY_SUPPLEMENT

First Reference product (dextrose, containing 25 g of carbohydrates)

Reference dextrose solution containing 25 g of available carbohydrates

DIETARY_SUPPLEMENT

Second Reference product (dextrose, containing 25 g of carbohydrates)

Reference dextrose solution containing 25 g of available carbohydrates

DIETARY_SUPPLEMENT

Third Reference product (dextrose, containing 25 g of carbohydrates)

Reference dextrose solution containing 25 g of available carbohydrates

DIETARY_SUPPLEMENT

High protein tube feed

Nutritional product containing 25 g of available carbohydrates

DIETARY_SUPPLEMENT

High-protein tube feed with additional amino acid

Nutritional product containing 25 g of available carbohydrates

DIETARY_SUPPLEMENT

Oral Nutritional Supplement for diabetes patients

Nutritional product containing 25 g of available carbohydrates

DIETARY_SUPPLEMENT

Oral Nutritional Supplement for diabetes patients (new formula)

Nutritional product containing 25 g of available carbohydrates

DIETARY_SUPPLEMENT

ONS for disease related malnutrition

Nutritional product containing 25 g of available carbohydrates

DIETARY_SUPPLEMENT

Plantbased ONS for disease related malnutrition

Nutritional product containing 25 g of available carbohydrates

Sponsors & Collaborators

  • INQUIS Clinical Research

    collaborator INDUSTRY
  • Nutricia Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-04
Primary Completion
2022-03-11
Completion
2022-03-11

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05179031 on ClinicalTrials.gov